Product Certification&
    Enterprise Certification

  • Ms.kathy
    Tel: 86-531-88870908

  • Mobile:18560059136
  • Tel:86-531-88870908
  • Fax:86-531-88870908
  • URL:http://www.hfdpharma.com
  • Province/state:shandong
  • City:jinan
  • Street:F Bldg. West Unit North Area of Univ. Tech. Garden Xinyu Rd. Jinan New & High Tech Industry Development Zone Shandong, China
  • MaxCard:
Home > Products >  Raloxifene hydrochloride

Raloxifene hydrochloride CAS NO.82640-04-8

  • FOB Price: USD 1 /Kilogram Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,MoneyGram
  • Available Specifications:

    99%(1-10)Kilogram

  • Product Details

Keywords

  • Raloxifene hcl
  • Raloxifene HCL
  • Raloxifene hydrochloride

Quick Details

  • ProName: Raloxifene hydrochloride
  • CasNo: 82640-04-8
  • Molecular Formula: C28H28ClNO4S
  • Appearance: yellow
  • Application: Raloxifene hydrochloride//cas:82640-04...
  • DeliveryTime: 3 days after payment
  • PackAge: as your requirement
  • Port: qingdao guangzhou shanghai dalian
  • ProductionCapacity: 23 Kilogram/Day
  • Purity: 98.5-101.5%
  • Storage: Avoid light, sealed
  • Transportation: by air or by sea
  • LimitNum: 1 Kilogram
  • Grade: Pharma Grade,Reagent Grade,Other
  • Grade: Pharma Grade
  • assay: 99%
  • High Purity: 99.9%
  • Standard: EP9, USP40
  • Sodium chloride: 0.1%

Superiority

raloxifene (marketed as evista by eli lilly and company) is an oralselective estrogen receptor modulator (serm) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. it is used in the prevention of osteoporosis in postmenopausal women.

in 2006, the national cancer institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk. a major adverse effect of tamoxifen is uterine cancer; raloxifene caused fewer cases of uterine cancer. tamoxifen increased the risk of cataracts, but raloxifene did not. both groups had more blood clots in veins and the lungs, but that side effect was more common with tamoxifen than raloxifene.[2][3][4] on september 14, 2007, the u.s. food and drug administration announced approval of raloxifene for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.[5]

an editorial in lancet oncology criticized the way that information about the drug was released.[6]

Details

Raloxifene
Systematic (IUPAC) name
[6-hydroxy-2-(4-hydroxyphenyl)- benzothiophen-3-yl]- [4-[2-(1-piperidyl)ethoxy]phenyl] -methanone
Clinical data
Trade names Evista
AHFS/Drugs.com monograph
MedlinePlus a698007
Licence data EMA:LinkUS FDA:link
Pregnancy cat. (AU) X (US)
Legal status  Prescription only
Routes Oral
Pharmacokinetic data
Bioavailability 2%
Protein binding 95%
Metabolism Gut glucuronidation[1]
CYP system not involved
Half-life 27.7 hours
Excretion Fecal
Identifiers
CAS number 84449-90-1 Yes
ATC code G03XC01
PubChem CID 5035
IUPHAR ligand 2820
DrugBank DB00481
ChemSpider 4859 Yes
UNII YX9162EO3I Yes
ChEBI CHEBI:8772 Yes
ChEMBL CHEMBL81 Yes
Chemical data
Formula C28H27NO4S 
Mol. mass 473.584 g/mol

 

Other products of this supplier

Other Related Products:82640-04-8 9005-27-0 201341-05-1 163252-36-6 53123-88-9 1722-62-9 99592-32-2 209216-23-9
Friend Links:hfdpharmahongfangde

lookchemhot product CAS New CAS